---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-032565"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-04-16T23:59:59+00:00"
generated_at: "2026-05-23T13:28:51.300559+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# INmune Bio receives favorable USPTO patentability opinion for CORDStrom platform

## Summary
- USPTO, as International Search Authority, issued favorable opinion on all claims of PCT/US25/17028 on April 8, 2025.
- Opinion confirms novelty, inventive step, and industrial applicability for CORDStrom pooled hucMSC therapy.
- Patent, once granted, would provide IP exclusivity for CORDStrom through at least 2045, subject to extensions.
- Company plans to accelerate U.S. national application via Patent Prosecution Highway (PPH) fast-track program.
- Follows recent Phase 2 trial data showing CORDStrom reduced pain and itch with early skin integrity signals.

## SEC filing metadata
- accession: 0001213900-25-032565
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025032565/0001213900-25-032565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025032565/ea0238598-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-032565
- JSON: https://secwatch.observer/filing/0001213900-25-032565.json
- Plain text: https://secwatch.observer/filing/0001213900-25-032565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.